What is the price target for IRWD stock?
10 analysts have analysed IRWD and the average price target is 5.46 USD. This implies a price increase of 50.33% is expected in the next year compared to the current price of 3.63.
IRONWOOD PHARMACEUTICALS INC (IRWD) Forecast, Price Target & Analyst Ratings
NASDAQ:IRWD • US46333X1081
Current stock price
3.63 USD
+0.03 (+0.83%)
At close:
3.55 USD
-0.08 (-2.2%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IRONWOOD PHARMACEUTICALS INC (IRWD).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.24
- Revenue Estimate
- 93.93M
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.46
Upside
+ 50.33%
From current price of $3.63 to mean target of $5.46, Based on 10 analyst forecasts
Low
$0.71
Median
$5.46
High
$10.50
Price Target Revisions
1 Month
10.31%
3 Months
114.00%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for IRWD. The average price target is 5.46 USD. This implies a price increase of 50.33% is expected in the next year compared to the current price of 3.63.
The average price target has been revised upward by 114% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.00%
IRWD was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about IRWD.
In the previous month the buy percentage consensus was at a similar level.
IRWD was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-05 | Citizens | Upgrade | Market Perform -> Market Outperform |
| 2026-01-05 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-15 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-04-15 | Jefferies | Downgrade | Buy -> Hold |
| 2025-04-14 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-01-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-01-22 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-09 | Leerink Partners | Initiate | Market Perform |
| 2024-08-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-08-09 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-05-10 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-03-01 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-02-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-01-17 | Craig-Hallum | Initiate | Buy |
| 2023-12-14 | Wells Fargo | Initiate | Overweight |
| 2023-09-28 | JMP Securities | Initiate | Market Outperform |
| 2023-05-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2022-08-16 | Wells Fargo | Maintains | Equal-Weight |
| 2022-04-22 | Piper Sandler | Initiate | Overweight |
| 2021-10-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-22 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-19 | Morgan Stanley | Maintains | Equal-Weight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.24
- Revenue Estimate
- 93.93M
- Revenue Q2Q
- 128.30%
- EPS Q2Q
- 274.86%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
141.07%
EPS (1 Month)
41.18%
EPS (3 Months)
1,100.00%
Next Earnings Summary
IRWD is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is 0.24 USD and the consensus revenue estimate is 93.93M USD.
The next earnings revenue estimate has been revised upward by 141.07% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 442.735M 7.83% | 351.41M -20.63% | 296.151M -15.72% | 467.77M 57.95% | 488.3M 4.39% | 499.83M 2.36% | 271.83M -45.62% | 172.89M -36.40% | 173.4M 0.29% | 210.12M 21.18% | 225.42M 7.28% | |
| EBITDA YoY % growth | 169.911M -32.51% | 97.728M -42.48% | 120.64M 23.44% | 312.48M 159.02% | 329.21M 5.35% | 352.97M 7.22% | 103.02M -70.81% | -58.14M -156.44% | -46.92M 19.30% | 19.38M 141.30% | 39.78M 105.26% | |
| EBIT YoY % growth | 168.336M -32.76% | 95.717M -43.14% | 118.759M 24.07% | 292.59M 146.37% | 308.81M 5.54% | 357.1M 15.64% | 86.7M -75.72% | -75.48M -187.06% | -64.26M 14.86% | 1.02M 101.59% | 30.09M 2,850.00% | |
| Operating Margin | 38.02% | 27.24% | 40.10% | 62.55% | 63.24% | 71.44% | 31.89% | -43.66% | -37.06% | 0.49% | 13.35% | |
| EPS YoY % growth | 0.64 -34.02% | 0.02 -96.88% | 0.23 1,050.00% | 1.38 498.70% | 1.49 7.90% | 1.59 6.86% | 0.50 -68.20% | -0.27 -152.53% | -0.15 42.31% | 0.23 250.00% | 0.33 44.44% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.24 274.86% | 0.33 138.00% | 0.39 64.33% | 0.41 4,180.00% | 0.21 -14.58% | 0.32 -5.10% | 0.39 -1.72% | 0.43 6.25% | 0.30 41.46% | 0.40 25.81% | 0.41 5.26% | 0.43 -1.18% |
| Revenue Q2Q % growth | 93.93M 128.30% | 121.19M 42.18% | 127.77M 4.68% | 124.85M 161.69% | 105.16M 11.96% | 129.23M 6.63% | 130.97M 2.50% | 135.97M 8.91% | 110.36M 4.94% | 135.66M 4.98% | 137.5M 4.99% | 142.8M 5.02% |
| EBITDA Q2Q % growth | 50.337M 595.00% | 77.01M 67.35% | 92.616M 17.08% | 92.463M 996.31% | 64.872M 28.88% | 88.944M 15.50% | 90.678M -2.09% | 95.676M 3.47% | 74.154M 14.31% | 99.45M 11.81% | 101.29M 11.70% | 106.59M 11.41% |
| EBIT Q2Q % growth | 45.747M 529.63% | 72.42M 60.68% | 87.516M 12.66% | 87.363M 1,233.18% | 58.752M 28.43% | 82.824M 14.37% | 84.558M -3.38% | 89.556M 2.51% | 68.034M 15.80% | 93.33M 12.68% | 95.166M 12.55% | 100.47M 12.19% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
90.41%
EPS Next 5 Year
-25.82%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
17.87%
Revenue Next 5 Year
-10.75%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
50.56%
EBIT Next 5 Year
-20.70%
IRONWOOD PHARMACEUTICALS INC / IRWD Forecast FAQ
Can you provide the upcoming earnings date for IRONWOOD PHARMACEUTICALS INC?
IRONWOOD PHARMACEUTICALS INC (IRWD) will report earnings on 2026-04-30.
What are the consensus estimates for IRWD stock next earnings?
The consensus EPS estimate for the next earnings of IRONWOOD PHARMACEUTICALS INC (IRWD) is 0.24 USD and the consensus revenue estimate is 93.93M USD.
What is the expected long term growth rate for IRONWOOD PHARMACEUTICALS INC (IRWD)?
The expected long term growth rate for IRONWOOD PHARMACEUTICALS INC (IRWD) is 17.87%.